tiprankstipranks
Trending News
More News >
Relmada Therapeutics Inc (RLMD)
:RLMD
US Market

Relmada Therapeutics (RLMD) Income Statement

Compare
395 Followers

Relmada Therapeutics Income Statement

Last quarter (Q3 2025), Relmada Therapeutics's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q3, Relmada Therapeutics's net income was $-10.09M. See Relmada Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Operating Expenses
$ 83.89M$ 103.70M$ 161.25M$ 125.70M$ 60.84M
Depreciation and Amortization
$ 0.00$ 103.70M$ 2.00K$ 1.26K$ 3.75K
EBITDA
$ -83.89M$ 4.91M$ -161.25M$ -125.70M$ -59.33M
Operating Income
$ -83.89M$ -103.70M$ -161.25M$ -125.70M$ -60.84M
Other Income/Expenses
$ 3.91M$ 4.91M$ 4.21M$ -48.32K$ 1.38M
Pretax Income
$ -79.98M$ -98.79M$ -157.04M$ -125.75M$ -59.46M
Net Income
$ -79.98M$ -98.79M$ -157.04M$ -125.75M$ -59.46M
Per Share Metrics
Basic EPS
$ -2.65$ -3.28$ -5.30$ -7.16$ -3.81
Diluted EPS
$ -2.65$ -3.28$ -5.30$ -7.16$ -3.81
Weighted Average Shares Outstanding
30.16M 30.10M 29.63M 17.55M 15.59M
Weighted Average Shares Outstanding (Diluted)
30.16M 30.10M 29.63M 17.55M 15.59M
Currency in USD

Relmada Therapeutics Earnings and Revenue History